TOMM40 is located on chromosome 19, is in linkage disequilibrium with apolipoprotein E (APOE), andis reported in several genome-wide association studies to be associated with Alzheimer’s disease (AD).
Objective:
Assess APOE and TOM40 and mitochondrial genes as blood biomarkers for AD.
Methods:
We examined TOMM40, PTEN-induced putative kinase 1 (PINK1), Parkin RBR E3 ubiquitin protein ligase (PARK2), and APOE mRNA expression in relation to the methylation rates of CpG sites in the upstream region of TOMM40exon 1 in peripheral leukocytes and TOMM40523 polyT genotypes in 60 AD and age- and sex-matched control subjects.
Results:
TOMM40 mRNA expression was significantly lower in AD subjects (0.87±0.18 versus 1.0±0.23, p = 0.005), and PINK1 mRNA expression was higher in AD subjects (1.5±0.61 versus 1.0±0.52, p < 0.001). TOMM40 mRNA expression was significantly correlated with the Mini-Mental State Examination total score (r = 0.290, p = 0.027). There was no expressional change in peripheral APOE mRNA in either AD or control subjects (p = 0.32). Methylation rates in the upstream region of TOMM40exon 1 were not different between AD and control subjects (average rate: 1.37±0.99 versus 1.39±1.20, p = 0.885), and TOMM40523 polyT genotypes were also not different between AD and control subjects (p = 0.67).
Conclusion:
TOMM40 mRNA expression was lower in AD subjects and was correlated with cognitive decline. Significant changes in both TOMM40 and PINK1 mRNA may be related to mitochondrial dysfunction.
GlennerGG, WongCW (2012) Alzheimer’s disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein. 1984. Biochem Biophys Res Commun425, 534–539.
2.
De StrooperB (2010) Proteases and proteolysis in Alzheimer disease: A multifactorial view on the disease process. Physiol Rev90, 465–494.
RamananVK, RisacherSL, NhoK, KimS, SwaminathanS, ShenL, ForoudTM, HakonarsonH, HuentelmanMJ, AisenPS, PetersenRC, GreenRC, JackCR, KoeppeRA, JagustWJ, WeinerMW, SaykinAJ (2014) APOE and BCHE as modulators of cerebral amyloid deposition: A florbetapir PET genome-wide association study. Mol Psychiatry19, 351–357.
11.
LiH, WettenS, LiL, St JeanPL, UpmanyuR, SurhL, HosfordD, BarnesMR, BrileyJD, BorrieM, ColettaN, DelisleR, DhallaD, EhmMG, FeldmanHH, FornazzariL, GauthierS, GoodgameN, GuzmanD, HammondS, HollingworthP, HsiungGY, JohnsonJ, KellyDD, KerenR, KerteszA, KingKS, LovestoneS, Loy-EnglishI, MatthewsPM, OwenMJ, PlumptonM, Pryse-PhillipsW, PrinjhaRK, RichardsonJC, SaundersA, SlaterAJ, St George-HyslopPH, StinnettSW, SwartzJE, TaylorRL, WherrettJ, WilliamsJ, YarnallDP, GibsonRA, IrizarryMC, MiddletonLT, RosesAD (2008) Candidate single-nucleotide polymorphisms from a genomewide association study of Alzheimer disease. Arch Neurol65, 45–53.
12.
CorderEH, SaundersAM, StrittmatterWJ, SchmechelDE, GaskellPC, SmallGW, RosesAD, HainesJL, Pericak-VanceMA (1993) Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science261, 921–923.
13.
HumphriesAD, StreimannIC, StojanovskiD, JohnstonAJ, YanoM, HoogenraadNJ, RyanMT (2005) Dissection of the mitochondrial import and assembly pathway for human Tom40. J Biol Chem280, 11535–11543.
SwerdlowRH (2012) Mitochondria and cell bioenergetics: Increasingly recognized components and a possible etiologic cause of Alzheimer’s disease. Antioxid Redox Signal16, 1434–1455.
16.
RosesAD (2010) An inherited variable poly-T repeat genotype in TOMM40 in Alzheimer disease. Arch Neurol67, 536–541.
17.
LinnertzC, AndersonL, GottschalkW, CrenshawD, LutzMW, AllenJ, SaithS, MihovilovicM, BurkeJR, Welsh-BohmerKA, RosesAD, Chiba-FalekO (2014) The cis-regulatory effect of an Alzheimer’s disease-associated poly-T locus on expression of TOMM40 and apolipoprotein E genes. Alzheimers Dement10, 541–551.
18.
GohLK, LimWS, TeoS, VijayaraghavanA, ChanM, TayL, NgTP, TanCH, LeeTS, ChongMS (2015) TOMM40 alterations in Alzheimer’s disease over a 2-year follow-up period. J Alzheimers Dis44, 57–61.
KitadaT, AsakawaS, HattoriN, MatsumineH, YamamuraY, MinoshimaS, YokochiM, MizunoY, ShimizuN (1998) Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature392, 605–608.
21.
ChoiJ, RavipatiA, NimmagaddaV, SchubertM, CastellaniRJ, RussellJW (2014) Potential roles of PINK1 for increased PGC-1alpha-mediated mitochondrial fatty acid oxidation and their associations with Alzheimer disease and diabetes. Mitochondrion18, 41–48.
22.
Martin-MaestroP, GarginiR, PerryG, AvilaJ, Garcia-EscuderoV (2016) PARK2 enhancement is able to compensate mitophagy alterations found in sporadic Alzheimer’s disease. Hum Mol Genet25, 792–806.
23.
El GaamouchF, JingP, XiaJ, CaiD (2016) Alzheimer’s disease risk genes and lipid regulators. J Alzheimers Dis53, 15–29.
24.
BertolinG, Ferrando-MiguelR, JacoupyM, TraverS, GrenierK, GreeneAW, DauphinA, WaharteF, BayotA, SalameroJ, LombesA, BulteauAL, FonEA, BriceA, CortiO (2013) The TOMM machinery is a molecular switch in PINK1 and PARK2/PARKIN-dependent mitochondrial clearance. Autophagy9, 1801–1817.
25.
GuoM (2012) Drosophila as a model to study mitochondrial dysfunction in Parkinson’s disease. Cold Spring Harb Perspect Med2, pii: a009944.
26.
AbdolmalekyHM, SmithCL, FaraoneSV, ShafaR, StoneW, GlattSJ, TsuangMT (2004) Methylomics in psychiatry: Modulation of gene-environment interactions may be through DNA methylation. Am J Med Genet B Neuropsychiatr Genet127B, 51–59.
27.
UrdinguioRG, Sanchez-MutJV, EstellerM (2009) Epigenetic mechanisms in neurological diseases: Genes, syndromes, and therapies. Lancet Neurol8, 1056–1072.
28.
BellJT, PaiAA, PickrellJK, GaffneyDJ, Pique-RegiR, DegnerJF, GiladY, PritchardJK (2011) DNA methylation patterns associate with genetic and gene expression variation in HapMap cell lines. Genome Biol12, R10.
29.
PaiAA, BellJT, MarioniJC, PritchardJK, GiladY (2011) A genome-wide study of DNA methylation patterns and gene expression levels in multiple human and chimpanzee tissues. PLoS Genet7, e1001316.
30.
YoshinoY, MoriT, YoshidaT, YamazakiK, OzakiY, SaoT, FunahashiY, IgaJI, UenoSI (2016) Elevated mRNA expression and low methylation of SNCA in Japanese Alzheimer’s disease subjects. J Alzheimers Dis54, 1349–1357.
31.
FunahashiY, YoshinoY, YamazakiK, MoriY, MoriT, OzakiY, SaoT, OchiS, IgaJI, UenoSI (2017) DNA methylation changes at SNCA intron 1 in patients with dementia with Lewy bodies. Psychiatry Clin Neurosci71, 28–35.
32.
McKhannGM, KnopmanDS, ChertkowH, HymanBT, JackCRJr, KawasCH, KlunkWE, KoroshetzWJ, ManlyJJ, MayeuxR, MohsRC, MorrisJC, RossorMN, ScheltensP, CarrilloMC, ThiesB, WeintraubS, PhelpsCH (2011) The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement7, 263–269.
33.
FolsteinMF, FolsteinSE, McHughPR (1975) “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res12, 189–198.
34.
RosenWG, MohsRC, DavisKL (1984) A new rating scale for Alzheimer’s disease. Am J Psychiatry141, 1356–1364.
35.
HughesCP, BergL, DanzigerWL, CobenLA, MartinRL (1982) A new clinical scale for the staging of dementia. Br J Psychiatry140, 566–572.
36.
MontgomerySA, AsbergM (1979) A new depression scale designed to be sensitive to change. Br J Psychiatry134, 382–389.
37.
CummingsJL, MegaM, GrayK, Rosenberg-ThompsonS, CarusiDA, GornbeinJ (1994) The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia. Neurology44, 2308–2314.
38.
AndersenCL, JensenJL, OrntoftTF (2004) Normalization of real-time quantitative reverse transcription-PCR data: A model-based variance estimation approach to identify genes suited for normalization, applied to bladder and colon cancer data sets. Cancer Res64, 5245–5250.
39.
CarrolED, SalwayF, PepperSD, SaundersE, MankhamboLA, OllierWE, HartCA, DayP (2007) Successful downstream application of the Paxgene Blood RNA system from small blood samples in paediatric patients for quantitative PCR analysis. BMC Immunol8, 20.
40.
WatanabeSY, IgaJ, IshiiK, NumataS, ShimoderaS, FujitaH, OhmoriT (2015) Biological tests for major depressive disorder that involve leukocyte gene expression assays. J Psychiatr Res66-67, 1–6.
41.
GuoH, TabaraY, IgaseM, YamamotoM, OchiN, KidoT, UetaniE, TaguchiK, MikiT, KoharaK (2010) Abnormal nocturnal blood pressure profile is associated with mild cognitive impairment in the elderly: The J-SHIPP study. Hypertens Res33, 32–36.
42.
KandaY (2013) Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant48, 452–458.
43.
LeeTS, GohL, ChongMS, ChuaSM, ChenGB, FengL, LimWS, ChanM, NgTP, KrishnanKR (2012) Downregulation of TOMM40 expression in the blood of Alzheimer disease subjects compared with matched controls. J Psychiatr Res46, 828–830.
44.
ChongMS, GohLK, LimWS, ChanM, TayL, ChenG, FengL, NgTP, TanCH, LeeTS (2013) Gene expression profiling of peripheral blood leukocytes shows consistent longitudinal downregulation of TOMM40 and upregulation of KIR2DL5A, PLOD1, and SLC2A8 among fast progressors in early Alzheimer’s disease. J Alzheimers Dis34, 399–405.
45.
LandauSM, HarveyD, MadisonCM, ReimanEM, FosterNL, AisenPS, PetersenRC, ShawLM, TrojanowskiJQ, JackCR Jr, WeinerMW, JagustWJ (2010) Comparing predictors of conversion and decline in mild cognitive impairment. Neurology75, 230–238.
46.
ManczakM, CalkinsMJ, ReddyPH (2011) Impaired mitochondrial dynamics and abnormal interaction of amyloid beta with mitochondrial protein Drp1 in neurons from patients with Alzheimer’s disease: Implications for neuronal damage. Hum Mol Genet20, 2495–2509.
47.
SwerdlowRH, BurnsJM, KhanSM (2014) The Alzheimer’s disease mitochondrial cascade hypothesis: Progress and perspectives. Biochim Biophys Acta1842, 1219–1231.
48.
GispertS, RicciardiF, KurzA, AzizovM, HoepkenHH, BeckerD, VoosW, LeunerK, MullerWE, KudinAP, KunzWS, ZimmermannA, RoeperJ, WenzelD, JendrachM, Garcia-ArencibiaM, Fernandez-RuizJ, HuberL, RohrerH, BarreraM, ReichertAS, RubU, ChenA, NussbaumRL, AuburgerG (2009) Parkinson phenotype in aged PINK1-deficient mice is accompanied by progressive mitochondrial dysfunction in absence of neurodegeneration. PLoS One4, e5777.
KujothGC, HionaA, PughTD, SomeyaS, PanzerK, WohlgemuthSE, HoferT, SeoAY, SullivanR, JoblingWA, MorrowJD, Van RemmenH, SedivyJM, YamasobaT, TanokuraM, WeindruchR, LeeuwenburghC, ProllaTA (2005) Mitochondrial DNA mutations, oxidative stress, and apoptosis in mammalian aging. Science309, 481–484.
51.
CruchagaC, NowotnyP, KauweJS, RidgePG, MayoK, BertelsenS, HinrichsA, FaganAM, HoltzmanDM, MorrisJC, GoateAM (2011) Association and expression analyses with single-nucleotide polymorphisms in TOMM40 in Alzheimer disease. Arch Neurol68, 1013–1019.
52.
EtoM, WatanabeK, IshiiK (1986) Reciprocal effects of apolipoprotein E alleles (epsilon 2 and epsilon 4) on plasma lipid levels in normolipidemic subjects. Clin Genet29, 477–484.
53.
WangXL, McCredieRM, WilckenDE (1995) Polymorphisms of the apolipoprotein E gene and severity of coronary artery disease defined by angiography. Arterioscler Thromb Vasc Biol15, 1030–1034.
54.
AraiH, YamamotoA, MatsuzawaY, SaitoY, YamadaN, OikawaS, MabuchiH, TeramotoT, SasakiJ, NakayaN, ItakuraH, IshikawaY, OuchiY, HoribeH, EgashiraT, HattoriH, KitaT (2007) Polymorphisms of apolipoprotein E and methylenetetrahydrofolate reductase in the Japanese population. J Atheroscler Thromb14, 167–171.
55.
OuT, Yamakawa-KobayashiK, ArinamiT, AmemiyaH, FujiwaraH, KawataK, SaitoM, KikuchiS, NoguchiY, SugishitaY, HamaguchiH (1998) Methylenetetrahydrofolate reductase and apolipoprotein E polymorphisms are independent risk factors for coronary heart disease in Japanese: A case-control study. Atherosclerosis137, 23–28.
56.
KoboriS, NakamuraN, UzawaH, ShichiriM (1988) Influence of apolipoprotein E polymorphism on plasma lipid and apolipoprotein levels, and clinical characteristics of type III hyperlipoproteinemia due to apolipoprotein E phenotype E2/2 in Japan. Atherosclerosis69, 81–88.
57.
LutzMW, CrenshawDG, SaundersAM, RosesAD (2010) Genetic variation at a single locus and age of onset for Alzheimer’s disease. Alzheimers Dement6, 125–131.
58.
MinagawaH, GongJS, JungCG, WatanabeA, Lund-KatzS, PhillipsMC, SaitoH, MichikawaM (2009) Mechanism underlying apolipoprotein E (ApoE) isoform-dependent lipid efflux from neural cells in culture. J Neurosci Res87, 2498–2508.
59.
AkramA, SchmeidlerJ, KatselP, HofPR, HaroutunianV (2012) Association of ApoE and LRP mRNA levels with dementia and AD neuropathology. Neurobiol Aging33, 628.e1–628.e14.
60.
JooJE, HidenU, LassanceL, GordonL, MartinoDJ, DesoyeG, SafferyR (2013) Variable promoter methylation contributes to differential expression of key genes in human placenta-derived venous and arterial endothelial cells. BMC Genomics14, 475.
VenzaM, VisalliM, CatalanoT, BiondoC, BeninatiC, TetiD, VenzaI (2016) DNA methylation-induced E-cadherin silencing is correlated with the clinicopathological features of melanoma. Oncol Rep35, 2451–2460.
63.
PengR, LiuH, PengH, ZhouJ, ZhaH, ChenX, ZhangL, SunY, YinP, WenL, WuT, ZhangZ (2015) Promoter hypermethylation of let-7a-3 is relevant to its down-expression in diabetic nephropathy by targeting UHRF1. Gene570, 57–63.
64.
LunnonK, KeohaneA, PidsleyR, NewhouseS, Riddoch-ContrerasJ, ThubronEB, DevallM, SoininenH, KloszewskaI, MecocciP, TsolakiM, VellasB, SchalkwykL, DobsonR, MalikAN, PowellJ, LovestoneS, HodgesA (2017) Mitochondrial genes are altered in blood early in Alzheimer’s disease. Neurobiol Aging53, 36–47.
65.
DelbarbaA, AbateG, PrandelliC, MarzianoM, BuizzaL, Arce VarasN, NovelliA, CuetosF, MartinezC, LanniC, MemoM, UbertiD (2016) Mitochondrial alterations in peripheral mononuclear blood cells from Alzheimer’s disease and mild cognitive impairment patients. Oxid Med Cell Longe2016, 5923938.
